<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Spreading <z:hpo ids='HP_0000716'>depressions</z:hpo> (SDs) occur in experimental focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and contribute to lesion evolution </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="68" ids="48706">antagonists</z:chebi> inhibit SDs and reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="2" pm="."><plain>The glycine site on the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor complex offers a therapeutic target for <z:hpo ids='HP_0011009'>acute</z:hpo> focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, potentially devoid of many side effects associated with competitive and non-competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated the effect of the glycine <z:chebi fb="68" ids="48706">antagonist</z:chebi>, ZD9379, on SDs and <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Male Sprague-Dawley rats (n = 18) weighing 290 to 340 g undergoing permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) were randomly and blindly assigned to receive drug or placebo: Group 1 (pre-MCAO treatment group, n = 5) a 5 mg/kg bolus of ZD9379 over 5 minutes followed by 5 mg/kg/hour drug infusion for 4 hours beginning 30 minutes before MCAO; Group 2 (post-MCAO treatment group, n = 7) a 5 mg/kg bolus of ZD9379 30 minutes after MCAO followed by 5 mg/kg/hour drug infusion for 4 hours; and Group 3 (control group, n = 6) vehicle for 5 hours beginning 30 minutes before MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>SDs were monitored electrophysiologically for 4.5 hours following MCAO by continuous recording of cortical direct current (DC) potentials and electrocorticogram (ECoG) </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was measured 24 hours after MCAO by 2,3,5 triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining </plain></SENT>
<SENT sid="7" pm="."><plain>Corrected <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was 90 +/- 72 mm3 (mean +/- standard deviation) in Group 1, 105 +/- 46 mm3 in Group 2, and 226 +/- 41 mm3 in Group 3 (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>The corresponding numbers of SDs in the 3 groups were 8.2 +/- 5.8, 8.1 +/- 2.5, and 16.0 +/- 5.1, respectively (P &lt; .01) </plain></SENT>
<SENT sid="9" pm="."><plain>When <z:hpo ids='HP_0000001'>all</z:hpo> animals (n = 18) were analyzed, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and the number of SDs were significantly correlated (r = .68, P = .002) </plain></SENT>
<SENT sid="10" pm="."><plain>This study demonstrated that ZD9379 initiated before or after MCAO significantly reduced the number of SDs and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in a permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model, implying that ZD9379 is neuroprotective and its neuroprotective effect may be related to inhibiting <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-related SDs </plain></SENT>
</text></document>